AUPH
Aurinia Pharmaceuticals Inc.Healthcare · $2.1B market cap
Verdict
We can't put a fair value on AUPH right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow AUPH
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 10, 2026: no open-market purchases and 1 sale worth $190K. Why purchases matter
Sales
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works